{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AL001",
    "query": {
      "intervention": "AL001"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T15:50:10.856Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04374136",
      "title": "A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Frontotemporal Dementia"
      ],
      "interventions": [
        {
          "name": "AL001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Open label - AL001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alector Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "25 Years to 85 Years"
      },
      "enrollment_count": 119,
      "start_date": "2020-07-23",
      "completion_date": "2026-01-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-09-02T15:50:10.856Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04374136"
    },
    {
      "nct_id": "NCT07540338",
      "title": "A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bipolar I Disorder"
      ],
      "interventions": [
        {
          "name": "AL001",
          "type": "DRUG"
        },
        {
          "name": "Lithium carbonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alzamend Neuro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-05-11",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-02T15:50:10.856Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07540338"
    },
    {
      "nct_id": "NCT06921590",
      "title": "A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Neurology"
      ],
      "interventions": [
        {
          "name": "AL001",
          "type": "DRUG"
        },
        {
          "name": "Lithium Carbonate Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alzamend Neuro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 15,
      "start_date": "2025-05-09",
      "completion_date": "2025-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-02T15:50:10.856Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06921590"
    },
    {
      "nct_id": "NCT03636204",
      "title": "A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Frontotemporal Dementia"
      ],
      "interventions": [
        {
          "name": "AL001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Alector Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 64,
      "start_date": "2018-09-14",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-09-02T15:50:10.856Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03636204"
    },
    {
      "nct_id": "NCT05363293",
      "title": "Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Healthy Non-elderly and Elderly Adults"
      ],
      "interventions": [
        {
          "name": "AL001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alzamend Neuro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 65,
      "start_date": "2022-05-04",
      "completion_date": "2023-05-15",
      "has_results": true,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-09-02T15:50:10.856Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05363293"
    },
    {
      "nct_id": "NCT03987295",
      "title": "A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Frontotemporal Dementia"
      ],
      "interventions": [
        {
          "name": "AL001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alector Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 33,
      "start_date": "2019-09-27",
      "completion_date": "2024-06-05",
      "has_results": true,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-09-02T15:50:10.856Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03987295"
    },
    {
      "nct_id": "NCT06111014",
      "title": "Continuation Study for Latozinemab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neurodegenerative Diseases"
      ],
      "interventions": [
        {
          "name": "Latozinemab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alector Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2023-12-08",
      "completion_date": "2026-01-07",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-09-02T15:50:10.856Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Rochester, Minnesota • New York, New York + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06111014"
    },
    {
      "nct_id": "NCT05053035",
      "title": "A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "AL001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alector Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-09-02",
      "completion_date": "2022-10-28",
      "has_results": true,
      "last_update_posted_date": "2025-06-18",
      "last_synced_at": "2026-09-02T15:50:10.856Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Boston, Massachusetts • St Louis, Missouri",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05053035"
    }
  ]
}